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ABSTRACT
The human gastrointestinal (GI) tract microbiota plays a
pivotal role in our health. For more than a decade a major
input for describing the diversity of the GI tract microbiota
has been derived from the application of small subunit
ribosomal RNA (SSU rRNA)-based technologies. These
not only provided a phylogenetic framework of the GI tract
microbiota, the majority of which has not yet been
cultured, but also advanced insights into the impact of
host and environmental factors on the microbiota
community structure and dynamics. In addition, it
emerged that GI tract microbial communities are host and
GI tract location-specific. This complicates establishing
relevant links between the host’s health and the presence
or abundance of specific microbial populations and argues
for the implementation of novel high-throughput technol-
ogies in studying the diversity and functionality of the GI
tract microbiota. Here, we focus on the recent develop-
ments and applications of phylogenetic microarrays based
on SSU rRNA sequences and metagenomics approaches
exploiting rapid sequencing technologies in unravelling the
secrets of our GI tract microbiota.
The human gastrointestinal (GI) tract consists of
different and connected organs that are involved in
supplying the human body with nutrients and
energy sources by the conversion and absorption of
food. The human GI tract has a well-known
anatomical architecture and is approximately 7 m
long with a surface area of approximately 300 m2
in adults.1 Since it is continuously exposed to the
outside environment, the GI tract has several
protection systems. These include the low pH in
the stomach, the coverage of the complete GI tract
with a mucus layer, an enormous army of immune
cells that lie beneath this mucus layer, and the
presence of commensal microbes that abundantly
colonise the GI tract. These microbial communities
are collectively called commensal microbiota or GI
tract microbiota. This GI tract microbiota is
distributed along the entire GI tract, with the
density and diversity increasing from the stomach
to the colon. The acknowledged functions of the
GI tract microbiota include the conversion of
indigestible food components2 3 and the produc-
tion of essential vitamins and co-factors.
However, our understanding of the GI tract
microbiota is fragmented, which is due to the
limited accessibility of the different parts of the
GI tract and the immensely complex and diverse
community structure of the GI tract microbiota
which differs between individuals, intestinal
location and age groups.4
THE GASTROINTESTINAL TRACT MICROBIOTA
The myriad of microbial cells in the GI tract, which
outnumber our body cells by a factor of at least 10,
has a large species diversity and consists of
cultivated species as well as those that have not
yet been cultured. A recent estimation of the
cultivable fraction of the GI tract microbiota
includes 442 bacterial, three archaeal, and 17
eukaryotic species.5 However, it is evident that
any figures that report the known diversity of the
GI tract microbiota are continuously outdated due
to the steady reporting of novel intestinal inhabi-
tants. The majority of the currently available
cultivated representatives were discovered follow-
ing the introduction of anaerobic cultivation
technologies that are still being used as standard
tools.6 Novel bacteria that are still being isolated
from the human GI tract include a wide variety of
butyrate-producing bacteria belonging to the phy-
lum Firmicutes7 8 and bacteria belonging to the
phylum Bacteroidetes,9–12 which are abundant GI
tract phyla. In addition, the use of alternative
carbon sources brought the discovery of the first GI
tract representatives of the phyla Verrucomicrobia
and Lentisphearae, Akkermansia muciniphila and
Victivallis vadensis, respectively.13 14 A muciniphila,
especially, is a relevant isolate since it is a specialist
in mucin degradation and a very common and
abundant inhabitant of the GI tract which has
previously not been noted because of its small size
and specific carbon source requirements.13 15 16
Recently, novel culturing methods have been
developed which exploit microbeads or multi-
plexed solid surfaces and allow unconventional
and high-throughput culturing approaches.17 18
Such methods enable the simultaneous single-cell
cultivation of thousands of microbes, which is
essential for an appropriate study of the complex
and dense GI tract microbiota. Application of high-
throughput culturing is expected to expand our
knowledge of this neglected yet important element
of the human body. However, in the course of
evolution many GI tract microbes have developed
intimate relations with the host and with each
other, which makes microbes dependent on the
metabolic activity of another member of the
ecosystem and, therefore, almost impossible to
grow into pure culture.19 As an alternative, the use
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of small subunit ribosomal RNA (SSU rRNA) and
its corresponding gene has become established for
the classification and phylogenetic analysis of
microbes. The SSU rRNA gene includes approxi-
mately 1500 bp, which is a sufficient size for
comparative sequence analysis. SSU rRNA is
present in literally all organisms, and due to its
conserved function its sequence has remained
relatively conserved throughout evolution.
Nevertheless, it contains nine variable regions that
can be used for the identification and differentia-
tion of specific microbial species. In fact, all life
forms can be classified using the SSU rRNA
sequences and this has resulted in the discovery
of the Archaea as the third domain of life (Bacteria
and Eucarya are the other two domains) and the
construction of the revolutionary ‘‘tree of life’’.20 21
SSU rRNA and its corresponding gene can be
obtained directly from any environmental sample
without cultivation procedures and this allows the
detection of basically all members of an ecosystem,
including those that cannot be cultured yet.
Currently, over 400 000 SSU rRNA sequences are
available in DNA databases, which is far more than
for any other gene (http://www.arb-silva.de
(accessed 11 July 2008)). The first breakthrough
discovery of the SSU rRNA based analyses was
that cultivation represents only a small fraction
(estimated to be between 10 and 50%, depending
on the study) of the true microbial diversity within
the GI tract (table 1).
Exploring the diversity of an ecosystem by
comparative sequence analysis is based on identi-
fication of species-level phylogenetic types, ie,
phylotypes. Since variation of the SSU rRNA gene
sequence is present within the members of the
same species,40 41 and sometimes even between
different copies of the SSU rRNA gene within the
same microbial genome,42 phylotypes are defined as
groups of SSU rRNA gene sequences with a certain
level of similarity. However, the cut-off value of
SSU rRNA sequence similarity that is used for
phylotype definition is not consistent between
different studies and varies between 97 and 99%.
The higher the cut-off value, the higher is the
number of distinct phylotypes that will be found
in the same clone library.43 For diversity studies the
SSU rRNA sequences can be targeted using
different, often complementary, approaches.
Commonly applied approaches include cloning
and subsequent sequencing of SSU rRNA genes,
fingerprinting approaches such as denaturing gra-
dient gel electrophoresis (DGGE) and fluorescence
in situ hybridisation (FISH), which allows visuali-
sation of specific microbes. These approaches are
relatively low throughput and the choice of
approach will mainly depend on the question to
be answered. Cloning of SSU rRNA genes delivers
the most detailed phylogenetic information, fin-
gerprinting is most often used to compare micro-
bial communities and monitor their dynamics,
while FISH is the preferred approach to quantify
specific microbial populations. The combination
of these approaches has greatly advanced the
phylogenetic framework of the enormous micro-
bial diversity and novel insights into its ecology. It
has to be realised that neither of the methods for
studying GI tract microbiota gives absolutely
accurate information about the diversity of this
ecosystem, including the ‘‘gold standard’’ cloning
and sequencing-based studies. For example, the
Actinobacteria, which belong to the high G+C
Gram-positive bacteria, are frequently undetected
or under-represented in the clone libraries,
although they represent a dominant fraction of
GI tract microbiota, as has been demonstrated by
FISH using SSU rRNA-targeted oligonucleotide
probes.44 45
The composition of GI tract microbiota is most
often studied by analysing faecal samples, but the
microbiota of other intestinal samples, such as
specimens from the human colon and ileum, have
also been characterised.27 32 33 46 47 Fingerprinting
studies based on DGGE analysis of SSU rRNA
gene amplicons indicated that the dominant
community in faecal samples in about half of the
subjects studied does not necessarily represent that
found in other parts of the GI tract, including the
colonic mucosa.48 49 This most likely reflects the
fact that the number of microbes that are
associated with the mucosa is small compared to
the number of microbes present in the colon
lumen. Although most likely primed by mucosa-
associated microbes, the composition of the latter
can be affected by the growth on specific sub-
strates that reach the colon. If these substrates
become limited at the end of the colon, this could
also explain why certain abundant microbial
species in faeces are not viable any more and this
argues for studying samples derived from several
GI tract regions.50
Studies that employ SSU rRNA gene sequence
analysis are rapidly expanding our knowledge
about the diversity of the GI tract microbiota,
and only a decade after their introduction, the
number of molecularly detected GI tract phylo-
types has by far outnumbered the cultivated GI
tract species (fig 1). An intensive survey of the
publications focusing on the diversity of the
human GI tract microbiota demonstrated that
from more than 1200 microbes described, only
12% were recovered by application of both
molecular and cultivation-based approaches, while
the vast majority (,75%) was detected solely as an
SSU rRNA sequence.51 These values have to be
taken with caution as it has also to be realised that
most of the SSU rRNA sequences are retrieved
from intestinal samples, mostly faeces, from only a
dozen individuals. Considering the location and
individual-specific microbial composition of the GI
tract, this indicates that the 1200 species described
only reflect a fraction of the true microbial
diversity, which is estimated to consist of up to
1000 microbes per individual and more than 5000
microbes in total.23 33 51 52 This implies that we are
still at the beginning of describing the GI tract
microbial diversity. Hence, there is a need to
develop and apply high-throughput approaches in
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further culturing studies, SSU rRNA sequencing and
microbial diversity analysis, notably at different
locations in the GI tract. These are essential to
enable linking microbial populations to host-related
factors, such as host genotype, age, health status,
geographical location, ethnic origin, and diet.
PHYLOGENETIC MICROARRAY ANALYSIS OF
GASTROINTESTINAL TRACT MICROBES
As indicated above, the human GI tract contains a
microbiota, the diversity of which is beyond our
imagination given the total number of microbes,
and their location- and individual-specific composi-
tion. This complicates establishing links between
members of the microbiota and GI tract disorders.
At the moment, causal effects have been deter-
mined only for the well-studied and cultured
pathogens such as Helicobacter pylori, Listeria
monocytogenes, Clostridium difficile and members of
the Enterobacteriaceae.53 In addition, correlations
have been suggested between the health status of
individuals and the composition and activity of
their microbiota. Irritable bowel syndrome (IBS)
and intestinal bowel diseases (IBDs), such as
Crohn’s disease and ulcerative colitis, have fre-
quently been associated with a rather unstable and
disturbed microbiota composition in contrast to
healthy individuals.54–57 These differences have to
be taken with caution since they can be influenced
by several factors, including the use of medicine
that may affect the microbiota. In addition, the
unstable microbiota of patients with IBD can be
caused by the disease status of the patients as
differences in community structures were observed
in patients who relapsed versus those who were in
remission.54–57 Last but not least, the stability of the
microbiota in healthy individuals decreases when
the time span between the sampling increases, and
differs between microbial populations.5 It was
demonstrated that a significant fraction of micro-
bial phylotypes is continuously present in the GI
tract of a person over a 10 year time span, which
indicates that the microbiota consists of a stable
individual core of colonising microbes surrounded
by temporal visitors.5 Despite these individual
differences, there are indications that some micro-
bial phylotypes are shared by different people and
this led to the hypothesis that besides the
individual core of microbes representing the stable
colonisers in healthy individuals, humans also share
a common core of microbes in their GI tract.58 This
hypothesis expands a previously proposed hypoth-
esis that the human gastrointestinal microbiota is
diverse but it is dominated by a limited number of
bacterial species in everybody.59–61
As it is not yet possible to define the microbiota
of a healthy intestinal tract, it is equally difficult to
define the microbiota associated with an intestinal
disorder. Another factor that complicates such an
association is the fact that these GI tract disorders
have a largely undefined, complex and possibly
heterogeneous aetiology in which, in addition to
the microbiota, host genetics and environmental
factors also play a role. Moreover, our inability to
cultivate all members of the microbiota makes it
impossible to formulate hypotheses about the role
of uncultured microbes in health and disease as a
(partial) SSU rRNA sequence provides no informa-
tion about the function of an organism. Last but
not least, the individual-specific composition of the
GI tract microbiota is also an important factor that
complicates the establishment of links between
microbes and the health status of the host.22 62
Since different people are recruited by the different
research groups, for which each of them has a
favourite target microbe or methodology for
microbiota analysis, comparisons between differ-
ent studies are basically impossible. Moreover, as
the number of persons tested is still low, it is
evident that high-throughput analyses of the
microbiota using standardised methods are needed
to make statistically relevant links between the
presence or quantity of uncultured bacterial
populations and GI tract disorders.
The most commonly used high-throughput
analytical method is DNA microarrays. DNA
microarrays are basically glass surfaces, each the
size of a microscopic slide, that are spotted with
thousands of covalently linked DNA probes. These
DNA microarrays can be hybridised with DNA or
RNA and the most current applications include
monitoring gene expression (transcriptional profil-
ing) and detecting DNA sequence polymorphisms
or mutations in genomic DNA. However, it is also
possible to use DNA microarrays for diversity
analysis (fig 2). Guschin and colleagues63 described
the first phylogenetic microarray (or diversity
microarray) in which oligonucleotides complemen-
tary to SSU rRNA gene sequences of nitrifying
bacteria were used to detect and identify these
bacteria in environmental samples. Thereafter,
DNA microarray technology has been implemen-
ted in a variety of ecological studies in which not
only SSU rRNA genes, but also antibiotics resis-
tance genes were used as targets.64–69 Recently, the
great potential of using phylogenetic microarrays
to detect thousands of microbes simultaneously
was demonstrated by DeSantis and colleagues.70
Figure 1 Cumulative number of specific gastrointestinal
(GI) tract phylotypes detected with culture-dependent and
culture-independent approaches based on the data
provided in table 1.
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This study illustrated that the use of phylogenetic
microarrays is more powerful for the analysis of
microbial community structure than a canonical
clone library approach.70 Besides this general
phylogenetic microarray, there are also specific
microarrays that focus on the microbial commu-
nities in specific ecosystems5 71 72 (table 2). These
include a phylogenetic microarray that targets the
microbiota of the oral cavity and two microarrays
that focus on the microbiota of the human GI
tract.
The first studies in which phylogenetic micro-
arrays were used to characterise the GI tract
microbiota have illustrated the power of such an
approach to gain insights into the structure and
population dynamics in the GI tract (box 1). In one
study 14 newborn babies were monitored over a
year and the results showed that the microbiota of
these infants is relatively simple and individual-
specific, but chaotic in the early months of life
followed by a similar pattern of development
towards a more complex adult-like microbiota.77
These results confirm and expand earlier studies
performed using DGGE analysis.25 The direct
phylogenetic identification enabled by the micro-
array brought to light another remarkable observa-
tion: bifidobacteria were found to be only a minor
fraction of the total microbiota of the infants
analysed. This contrasts with observations in several
previous studies which showed that bifidobacteria
are the most dominant group in infants.78 79
Although such a surprising finding could be partially
explained by technical biases (eg, inadequate primer
sequence or inefficient cell lysis), a biological
explanation is also possible as infants from different
studies originated from different continents and
received different paediatric practices and diets.77
The disparity of findings of different studies
illustrates our present inability to define the normal
GI tract microbiota even of its simplified form,
which at present is in early infancy.
Besides focusing on the GI tract microbiota in
healthy individuals, the first phylogenetic micro-
array studies on people with a GI tract disorder
have also been performed.5 As indicated before, the
common GI tract disorders, such as IBD and IBS, are
complex since they are influenced by the microbiota
and host genetic and environmental factors80–83 and,
therefore, comprehensive and high-throughput
approaches are needed to gain insight into this
complexity. The phylogenetic microarray analysis
demonstrated that persons having a GI tract disorder
had distinct microbiotas compared to healthy
individuals and that the severity of the disease is
correlated with the significance of the difference
with the healthy group.5 A striking observation was
that patients with IBS had increased heterogeneity
among the microbiota composition compared to
healthy individuals.5 This could be explained by the
fact that IBS is known as a heterogeneous disorder
based on varying clinical symptoms.84 Despite this
increased heterogeneity of the GI tract microbiota, a
remarkable observation is that, in IBS, members of
the Firmicutes were affected the most dramatically.
This is in line with the previous phylogenetic
microarray studies which indicated that the
Firmicutes are more strongly affected by environ-
mental changes than are Bacteroidetes and
Actinobacteria.5 This suggests that the alterations
in the Firmicutes could be candidate biomarkers for
IBS. The Firmicutes is the most diverse and
abundant phylum within the GI tract microbiota
consisting of a wide variety of uncultured organisms.
As a result, the functionality of the majority of
Firmicutes is not known and it is difficult to
hypothesise what it might be. Therefore, explaining
the observed trends is only possible for a few
microbial groups, such as Roseburia spp., which are
among the butyrate-producing isolates from the
gut.85 For instance, Roseburia spp. were found to be
increased in patients suffering from diarrhoea-
predominant IBS,5 which adds to the controversy
about the effect of butyrate on human health.86 87
With respect to these GI tract disorders it is evident
that obtaining more insight into the function of
Firmicutes is crucial. To overcome the problem of
the fact that the majority of Firmicutes will remain
uncultured in the near future, culture-independent
approaches to study functionality are needed.
The first applications of phylogenetic micro-
arrays have already provided novel insights into the
microbiota composition and dynamics in relation
to health and disease and these approaches are
promising for future research. However, the
application of phylogenetic microarrays also has
its limitations, as does any other microbiological
approach. Phylogenetic microarray analyses are
dependent on the isolation of nucleic acids and
subsequent polymerase chain reaction (PCR)
amplification of SSU rRNA genes, which are
Table 2 Overview of small subunit ribosomal RNA (SSU rRNA)-based phylogenetic microarrays which are fruitful to gain insight into the microbial
diversity of the human gastrointestinal (GI) tract microbiota
Target microbes Number of target organisms SSU rRNA database Number of probes Reference (first author)
Human commensal isolates 40 bacterial species GenBank 120 Wang61
Sulfate-reducing bacteria All recognised lineages ARB* 132 Loy65
All microbes 842 prokaryotic subfamilies Greengenes, 15 March 2002 version{ 297851 DeSantis70
Human oral cavity microbes NA NA NA Smoot72
Known GI tract commensals and medically
relevant microbes
1590 bacterial and 39 archaeal
species
prokMSA SSU rDNA sequence database,
2004 version{
10500 Palmer73
Human GI tract microbiota 1140 bacterial species Human GI tract Microbiota database,
2006 version1
4809 Rajilic´-Stojanivic´5
*Described by Ludwig et al.74 {Described by DeSantis et al.75 {Described by DeSantis et al.76 1Described by Rajilic´-Stojanivic´ et al.51 NA, not available.
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vulnerable to technical biases. These are, unfortu-
nately, general drawbacks of culture-independent
technologies and should be minimised as much as
possible. Furthermore, phylogenetic microarrays
have a dynamic range that only covers the dominant
microbes present in the GI tract. On the other hand,
at present, there are numerous group- and species-
specific quantitative PCR (qPCR) assays that are
useful for quantification of different phylogenetic
groups belonging to the human GI tract micro-
biota.88–90 These specific PCR protocols can be
combined with phylogenetic microarray analysis,
which will allow determination of the diversity and
relative abundance within low abundant groups.
This could be of special interest for studying the
population dynamics of pathogens or probiotics as
they are usually present in low numbers.
In conclusion, the first phylogenetic microarray-
based studies provided novel insights into the GI
tract ecology by demonstrating correlations between
certain microbial populations and host factors. To
determine the significance of a certain correlation,
the next questions to be addressed are whether
this correlation reflects a causal relation and, if so,
what mechanisms underlie the observed effects.
Answering this type of question cannot be done by
SSU rRNA gene-based approaches, but need the
integration of functional-based approaches, includ-
ing the application of the so-called meta-‘‘omics’’
approaches in GI tract research, as will be discussed
in the next section.
METAGENOMICS AND OTHER COMMUNITY-
BASED APPROACHES
SSU rRNA-based approaches are fruitful for
describing the microbial diversity in the human
GI tract and finding potential links between
microbes and a certain health status. However,
the results obtained with such approaches cannot
be interpreted beyond the description of the
microbial diversity, since potential functions of
these microbes cannot be extracted from SSU
rRNA data. This means that a correlation between
a disease status and the presence of a microbe
cannot explain whether its presence is the result or
the cause of the disorder. This means that other
approaches are needed to gain insight into the
potential roles of microbes in the human GI tract
and how they are related to health and disease. In
this respect, much insight has been gained from
isolates that are known as pathogens and have
been well-characterised in the laboratory. Animal
and in vitro models have shed some light on the
strategies these microbes have to interact with the
host and, moreover, the availability of their
genome sequences allows the discovery of genes
involved in these interactions. Besides pathogens,
commensal bacteria and their role in the GI tract
have also been studied in a similar way. The
pioneering work of Gordon and co-workers91–94 and
that of others showed that microbial colonisation
improves nutritional and defensive functions of
host. Moreover, the impact of the host on the
microbe was also studied.94 95 These so-called
reductionist approaches provide insight into new
genes and functions of individual organisms, which
serve as models for community based studies.
Model systems have provided detailed insights
into mechanisms that underlie the communication
between host and microbe. However, there is still a
huge gap between understanding these interactions
in a model system and that in a complex ecosystem,
such as the human GI tract. One way to gain insight
into potential functions and activities of microbes
without the need of cultivation is by performing
metagenomics and other community approaches
Figure 2 Schematic
representation of high-
throughput analysis of
human gastrointestinal (GI)
tract microbiota via brute
force sequencing and
phylogenetic microarray
analysis. SSU rRNA, small
sub-unit ribosomal RNA.
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(box 1). Metagenomics is a DNA-based approach to
gain insights into the genetic potential of microbial
communities, while the other meta-‘‘omics’’
approaches focus on activity biomarkers, such as
messenger RNA, proteins or metabolites (fig 3).
Metagenomics is defined as the study of collected
genomes from an ecosystem that can be used to
study the phylogenetic, physical and functional
properties of microbial communities.96
Metagenomics is performed by extracting DNA
from the microbial community followed by cloning
of the DNA fragments in a suitable host (usually E
coli) using a vector, such as fosmid or bacterial
artificial chromosome vectors. This results in a
metagenomic library that can be used for sequence-
driven or function-driven analysis. Sequence-driven
analyses are basically performed to obtain a snap-
shot of the genetic diversity of an ecosystem, while
function-driven analyses are done to screen the
library for novel enzymes or particular functions of
interest.
Function-driven metagenomics offers great pos-
sibilities to discover new classes of genes with
specific functions. The screening for these features
requires functional transcription and translation of
the genes, which are located in the metagenome
clone, in the host that was used for the metagen-
ome library construction. E coli is the most
commonly used host for construction of the
metagnomic library and it is predicted that it can
express up to 40% of the functional potential from
randomly cloned environmental DNA.97 Function-
driven metagenomic studies based on enzyme
activity assays have already led to the discovery
of novel activities, such as b-glucanases in the
colon of mice,98 bacterial hydrolases in rumen,99
and antibiotic resistance in the oral cavity.100
Recently, a phenotyping approach was used to
screen for metagenomic clones that contain capa-
cities to modulate the growth of epithelial cells in
vitro.101 This approach showed that the identifica-
tion of potentially novel mechanisms of host–
microbe interactions in the GI tract is possible.
These types of screening methods can be very
useful to screen for beneficial or harmful functions
that are present in the GI tract microbiota.
Subsequently, the expression of the genes that
are responsible for the function under study can be
monitored in situ and serve as potential biomarkers
for intervention studies.
It has to be realised that functional screening is
quite laborious since relatively large metagenomic
libraries have to be screened to obtain a handful of
positives per enzyme screen.99 To overcome this
drawback, a high-throughput screening approach,
termed substrate-induced gene-expression screen-
ing was developed, which allowed fluorescence-
activated cell sorting, in which catabolic genes
were activated by various substrates.102 Although
this approach looks promising for high-throughput
screening of human GI tract microbiota to discover
novel enzyme-encoding genes, the positive identi-
fication relies on several host requirements, which
include the recognition and transport of the
inducing substrate and the ability of the host to
express the corresponding genes located on the
cloned insert.
Sequence-driven metagenomics approaches are
used to create a catalogue of the genetic potential
that is present in an ecosystem, which can be
fruitful to gain insight into the functionality of the
particular ecosystem. Sequence-driven metage-
nomics has already been applied to study a variety
of ecosystems and the first metagenomic approach
that was performed on the human GI tract
described the diversity of the viral community in
human faeces.103 This study revealed that the viral
community in faeces is very diverse consisting of
approximately 1200 viral genotypes from which
the majority of viral sequences had the highest
sequence similarity to phages that are known to
infect Gram-positive bacteria. As mentioned pre-
viously, Gram-positive bacteria, which include the
phyla Firmicutes and Actinobacteria, were identi-
fied as dominant members of the GI tract
microbiota in SSU rRNA gene-based studies. The
first prokaryotic sequence-driven metagenomic
approach focused on the SSU rRNA sequences
that are represented in the metagenomic libraries
from pooled faecal samples from healthy indivi-
duals and from patients with Crohn’s disease.104
This study demonstrated that Firmicutes are
significantly reduced in complexity in patients
with Crohn’s disease compared to healthy sub-
jects. This is in line with SSU rRNA gene-based
observations, including those in which phyloge-
netic microarrays were used.5 In another study the
‘‘mobile metagenome’’ of the human GI tract
microbiota was investigated. In this study trans-
poson-aided capture was developed and applied to
the study of the plasmid-encoded genes that are
present in the human GI tract.105 In addition to
genes involved in replication and mobilisation of
the plasmids, genes encoding for phosphoesterase
or phosphohydrolase enzymes could be detected.
Besides these targeted sequence-driven metage-
nomic approaches, large-scale sequence-driven
metagenomic approaches have also been applied
Box 1 Novel insights that have been gained from high-throughput
analysis of the human gastrointestinal (GI) tract microbiota
c The human GI tract microbiota is composed of numerous uncultured microbes
and predominated by Firmicutes, Bacteroidetes and Actinobacteria
c In healthy adults the human GI tract microbiota fluctuates around a stable
individual core of phylotypes that are affected by host genetics, environmental
and stochastic factors
c In infants the GI tract microbiota is succeeding from an unstable chaotic
community towards a stable adult community
c A reduction in the abundance and diversity of Firmicutes is frequently
associated with intestinal bowel diseases and irritable bowel syndrome
c The human GI tract microbiome is enriched in functions that are essential to
the human host
c The human GI tract microbiome from healthy human adults consists of a
functionally uniform core and is a hotspot for gene transfer
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to investigate the genetic potential in the GI tract
ecosystem.106 107 The first study demonstrated that
many genes in the colonic microbiota represent
functions that are essential to the host, such as
vitamin production, which have often been
ascribed to the microbiota.106 Remarkably,
sequences affiliated to Bacteroidetes, one of the
dominant microbial groups in the colon, were not
detected in this library, which indicated that cell
lysis, DNA extraction and cloning procedures can
have a major impact on the genetic diversity that
is represented in a library. Recently, a comparative
metagenomics approach was described to compare
and contrast the genetic diversity in the human
colon of 13 subjects, including adults and
infants.107 This study indicated that the human
microbiota is a hot spot for horizontal gene
transfer. Moreover, this study demonstrated that
the genomic features of infants were less complex
and individual-specific, while those of adults were
more complex with high functional uniformity
between individuals. The latter finding confirms
the proposal that all human GI tract microbiotas
share a common core of microbes, despite their
individual-specific composition.58
Sequence-driven approaches result in a wealth
of scattered pieces of sequences and this means
that special tools for post-metagenomic analysis
are indispensable. Although software packages
have been developed to re-assemble the genomic
fragments that are sequenced, a major limitation
of metagenomics is that the genetic diversity in
an ecosystem is enormous. Despite the contin-
uous development of novel, relatively cheap,
sequencing technologies, such as 454 pyrosequen-
cing,108 which will result in increased numbers of
metagenomic sequences, at the moment it is
almost impossible to obtain reasonable coverage
for complex ecosystems such as the human GI
tract microbiota. Nevertheless, this raw sequence
information can be analysed by comparative
metagenomics and these types of analyses can
already reveal the identification of genes that are
specific or enriched in a certain ecosystem or
niche.109 110
It has to be realised that the detection of genes in
a metagenomic library does not necessarily mean
that these are functionally important. Therefore,
metagenomics should be considered more as
catalogues for activity-based approaches and that
other meta-‘‘omics’’ approaches, which use RNA,
proteins and metabolites as targets, are better
approaches to gain insight into the activity and
functionally of the microbes in an ecosystem (fig 3).
These meta-‘‘omics’’ approaches are still in their
infancy,111 but we expect that they will be
extensively used in the near future.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
For more than a decade it has been recognised that
a major part of the human GI tract microbiota has
not been characterised by cultivation. This has led
to the implementation of sequence analysis of SSU
rRNA and its corresponding gene in studying the
human GI tract microbiota diversity and this has
provided tremendous expansion of our knowledge
about the ecology of the GI tract. However, these
approaches have indicated that the GI tract
microbiota is individual- and location-specific,
and that its diversity is enormous with thousands
of novel microbial species to be discovered.51 This
argues for the introduction of novel high-through-
put and comprehensive technologies for studying
the microbiota in the human GI tract, as described
in this paper.
The implementation of high-throughput phylo-
genetic microarrays allows the simultaneous
analysis of thousands of microbes in a single
experiment and, therefore, is very attractive for
studying the population dynamics of the GI tract
microbiota in health and disease. This resulted in
the discovery that the development of the micro-
biota in infants is initially chaotic but stabilises
towards an adult-like community after 1 year.77 In
addition, phylogenetic microarray analysis indi-
cated that the human microbiota fluctuates around
an individual core of stable colonisers.5 Last, but
not least, significant links have been established
between the presence or abundance of specific
groups of microbes and GI tract disorders such as
IBS and IBD.5 Therefore, it is already evident that
the implementation of phylogenetic microarrays in
GI tract research will increase our knowledge in the
near future. Nevertheless, the up-to-date status of
phylogenetic microarrays will always depend on
the discovery of novel GI tract inhabitants and,
therefore, ongoing sequencing of SSU rRNA gene
libraries and cultivation of the novel GI tract
inhabitants are indispensable.
It is evident that phylogenetic microarrays will
enable us to make correlations between microbial
Figure 3 Schematic representation of the metagenomics and other community-based
‘‘omics’’ approaches. SSU rRNA, small subunit ribosomal RNA.
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groups and characteristics of the host. However,
this will not lead to extrapolation of microbial
functions as the majority of GI tract microbes are
only known as a partial SSU rRNA gene. Therefore,
metagenomics and other meta-‘‘omics’’ approaches
are needed to gain insight into the genetic potential
and activity of GI tract microbiota. The field of these
meta-‘‘omics’’ is hardly 5 years old and their
application in the study of the human GI tract is
even younger. Therefore, the analysis and interpre-
tation of data derived from meta-‘‘omics’’
approaches are still in infancy. We expect many
novel technological procedures to be developed and
improved in the coming years, not only with respect
to wetlab technologies, such as pyrosequencing and
functional screening tools, but also in the field of
bioinformatics to analyse the enormous mass of data
that is obtained with such approaches. Nevertheless,
the first applications of meta-‘‘omics’’ approaches
have already demonstrated their power as discussed
in this paper and we expect this field to grow
explosively in the near future.
Only an integration of all reductionist and meta-
‘‘omics’’ approaches in the near future will provide
adequate understanding of GI tract microbiota, as
these approaches complement each other by
delivering different pieces of the GI tract puzzle.
For example, the analysis of different cell cultures
will result in the discovery of novel genes and
functions of individual organisms and therefore,
serve as milestones for meta-‘‘omics’’ approaches.
This integration is essential to explain data derived
from meta-‘‘omics’’ analysis, since the limitations
in our predictive capacity was demonstrated in the
first metaproteomics study of the human GI tract
microbiota.112
Overall, it will be a challenging future for GI
tract researchers. With the introduction of the
novel high-throughput technologies that are
described here, it will be possible, for the first
time, to obtain statistically relevant links between
microbial phylotypes and activities, and human
health. Ultimately, this will lead to the discovery
of biomarkers that will help us to understand and
predict the microbial life in our intestine, which is
the dream of a GI tract microbial ecologist.
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